Home > Insider Trading > Filing (0001441557-17-000004)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1187953	Creative Medical Technology Holdings Inc.	CELZ	Biological Products, (No Disgnostic Substances) (2836)	870622284

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1674492	Timothy Warbington	2017 W Peoria Ave Phoenix AZ 85029	President & Ceo	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-12-18	3,412,791	$0.01	61,553,876	No	4	S	Indirect	Entity
Common Stock	Disposition	2016-12-31	2,935,609	$0.10	58,618,267	No	4	S	Indirect	Entity

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Entity
No	4	S	Indirect	Entity

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	6,466,667	Direct
Common Stock	64,966,667	Indirect	Entity

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Warrants	$0.10	2016-09-30	2026-09-30	30,000	30,000	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2026-09-30	30,000	30,000	Indirect

Footnotes

Shares are held by Creative Medical Health, of which Mr. Warbington is President. Mr. Warbington disclaims beneficial ownership of such shares of common stock except to the extent of his pecuniary interest therein.
Warrants are held by Creative Medical Health, of which Mr. Warbington is President. Mr. Warbington disclaims beneficial ownership of such shares of common stock except to the extent of his pecuniary interest therein.
The transaction reported hereby represents a cancellation of debt owed by the reporting party to the purchaser. The total amount of debt exchanged for the common shares was $293,560.91, or $0.10 per share, the same price as shares of common stock purchased by the reporting party on September 30, 2016. As an incentive to enter into the transaction the reporting party granted to the purchaser an option to purchase up to 293,561 shares of the Issuer at $0.10 per share with such option expiring August 1, 2019.